For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Anergen, Inc.

Calculating rank

USPTO Granted Patents = 17

Forward Citations = 393

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Brian R Clark (9 out of 21 patents)

Somesh D Sharma (9 out of 21 patents)

Bishwajit Nag (8 out of 42 patents)

4. L Bernard Lerch (4 out of 6 patents)

5. Bernard L Lerch (2 out of 3 patents)

6. Michael A McCutcheon (2 out of 2 patents)

7. Nancy G Wehner (2 out of 2 patents)

8. Edward G Spack (2 out of 2 patents)

9. Wayne R Kindsvogel (1 out of 104 patents)

10. Jane A Gross (1 out of 52 patents)

11. Subramaniam Sriram (1 out of 8 patents)

12. Eva Pia Reich (1 out of 1 patent)

13. Harden M McConnell (1 out of 15 patents)

14. Prabha V Mukku (1 out of 1 patent)

15. Teresa Kendrick (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 6451314 - MHC conjugates useful in ameliorating autoimmunity (2002-09-17),

2. 6218132 - Method for monitoring T cell reactivity (2001-04-17),

3. 6106840 - MHC conjugates useful in ameliorating autoimmunity (2000-08-22),

4. 6060309 - Immune mediators and related methods (2000-05-09),

5. 6045796 - Vaccination with peptide of MHC class II molecules for treatment of (2000-04-04),

6. 6007820 - Purification and characterization of MHC-peptide complexes useful in (1999-12-28),

7. 5824315 - Binding affinity of antigenic peptides for MHC molecules (1998-10-20),

8. 5763585 - Method of making MHC-peptide complexes using metal chelate affinity (1998-06-09),

9. 5750356 - Method for monitoring T cell reactivity (1998-05-12),

10. 5734023 - MHC class II .beta. chain/peptide complexes useful in ameliorating (1998-03-31),

11. 5595881 - Method for the detection of antigen presenting cells (1997-01-21),

12. 5334391 - Intracellularly cleavable compounds (1994-08-02),

13. 5284935 - MHC-mediated toxic conjugates useful in ameliorating autoimmunity (1994-02-08),

14. 5260422 - MHC conjugates useful in ameliorating autoimmunity (1993-11-09),

15. 5194425 - MHC-mediated toxic conjugates useful in ameliorating autoimmunity (1993-03-16),

Company Overview

Anergen, Inc. is a biotechnology company based in Seattle, WA, focused on developing innovative therapies for autoimmune diseases. The organization specializes in harnessing the power of immunology to create treatments that modulate the immune response, aiming to improve patient outcomes in conditions where the immune system is dysregulated. Through its advanced research and development efforts, Anergen is committed to addressing significant unmet medical needs in the field of immunotherapy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

17 Patents

#117 in Seattle, WA

#403 in Washington

#18,903 in US

#35,948 in the World

Seattle, WA, United States of America

Anergen, Inc.

Forward Citations = 393

15 inventors:

Brian R Clark (9 out of 21 patents)

Somesh D Sharma (9 out of 21 patents)

Bishwajit Nag (8 out of 42 patents)

4. L Bernard Lerch (4 out of 6 patents)

5. Bernard L Lerch (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anergen, Inc.. Retrieved from https://idiyas.com/company/anergen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…